Praxis Precision Medicines, Inc. (PRAX) Stock: Price, Forecast & Analyst Target
Praxis Precision Medicines, Inc. (PRAX) — MoonshotScore 60/100 (Fair band), calculated Nov 18, 2026. Price $310.90 (+1.87%), as of the Nov 19, 2026 trading session; market cap $8.69B. Expected results Feb 18, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 11.66× (cash as of Sep 30, 2026) · expected results Feb 18, 2027
Praxis Precision Medicines, Inc. · PRAX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Praxis Precision Medicines is a clinical-stage developer of therapies for central nervous system disorders linked to abnormal neuronal activity, not a commercial drug company with recurring product sales. Its value rests on whether a broad investigational pipeline can produce approvals or partnership economics before research spending consumes the financial cushion.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Praxis Precision Medicines (PRAX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Sound; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- EPS beat 4 of the last 8 reports
- Altman Z 95.69 · Piotroski F 2
- ROE -29.4% · ROA -27.4% · current ratio 14.53 · earnings yield -4.0% · free-cash-flow yield -3.8%
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 59 | Fair | |
| 59 | Fair | |
| 58 | Fair | |
| 58 | Fair | |
| 60 | Fair | |
| 60 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $310.90 | |
| Change on the day | +1.87% | |
| 52-week range | $160.11–$392.70 | |
| Market capitalisation | $8.69B | — |
| Shares traded on the day | 630.3K | |
| Beta (volatility vs the S&P 500) | 2.84 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Praxis Precision Medicines (PRAX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Praxis Precision Medicines (PRAX), and what does it report?
Short answer · as of
Praxis designs compounds that alter neuronal signaling through GABAA receptors, calcium channels and sodium currents, alongside antisense programs for genetically defined epilepsies.
Research dated 2026-09-13.
Clinical development and licensing collaborations are the operating work; patients are not yet generating a recurring product-revenue stream.
Reported revenue has instead come from license and upfront payments, and recent periods recorded none. The income statement therefore measures the cost of advancing the pipeline, with research and development dominating expenses and recurring losses reflecting investment in investigational assets rather than weak demand for an established medicine.
What do the latest results show for Praxis Precision Medicines (PRAX)?
Short answer · as of
Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Research dated 2026-09-13.
The latest quarter remained pre-revenue and deeply loss-making, but the net and operating losses narrowed from the preceding period as research spending eased. Operating cash use also moderated, although it remained well above the pace seen earlier in the historical series.
Recent reported losses have come in ahead of analyst expectations, yet that comparison says little about clinical or commercial progress. The broader annual record shows research spending expanded sharply while the net loss widened, so the latest moderation has not yet established a sustained change in the cost base.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $64.20M Sep 30, 2026
- Latest quarter · SG&A
- $42.71M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$106.91M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | $64.20M | $42.71M | −$106.91M |
| Jun 30, 2026 | Not available | $69.42M | $27.49M | −$96.90M |
| Mar 31, 2026 | Not available | $77.99M | $27.87M | −$105.86M |
| Dec 31, 2025 | Not available | $77.51M | $19.54M | −$97.04M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue estimate
- $130,769 Nov 9, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 9, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 9, 2026 | Not available | $130,769 | −$3.2300 | −$3.5400 |
| Aug 6, 2026 | Not available | Provider row rejected | −$2.8700 | −$3.6700 |
| May 7, 2026 | Not available | $100,000 | −$3.2000 | −$3.5800 |
| Feb 19, 2026 | Not available | $66,667 | −$3.5000 | −$3.1259 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
What are the financial strengths and risks for Praxis Precision Medicines (PRAX)?
Short answer
Cash and short-term investments were $745.32M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$81.74M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments greatly exceed debt and current liabilities, while liquidity ratios indicate ample near-term coverage. At the recent operating and capital-spending pace, the available balance supports multiple years of development, giving Praxis meaningful room to fund trials without immediate dependence on operating revenue.
That cushion is not the same as self-funding. Operations continue to consume cash, the latest balance declined from the preceding quarter, and the market value stands far above net cash; valuation therefore depends primarily on investigational assets creating future economic value. Clinical failure, regulatory delay or an inability to secure attractive licensing terms would leave substantial research spending without a product-sales base, while the wide spread in longer-range revenue estimates shows how differently that conversion can unfold.
Data-derived red flags
- Negative return on equity (-29.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$81.74M Sep 30, 2026
- Previous quarter · operating cash flow
- −$77.64M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$81.74M | −$780,000 |
| Jun 30, 2026 | −$77.64M | −$240,000 |
| Mar 31, 2026 | −$86.05M | −$60,000 |
| Dec 31, 2025 | −$77.26M | $0.00 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Praxis Precision Medicines (PRAX)?
Short answer · as of
The next earnings report is expected on Feb 18, 2027. The number it tests is the $-13.48 EPS analysts carry for it.
Research dated 2026-09-13.
The next scheduled report should be read for the direction of research spending, operating cash use and the cash balance. Continued moderation across those measures would extend financial flexibility; renewed acceleration would shorten the time available for the pipeline to create value.
Revenue deserves a different test from that applied to a commercial drugmaker. A reappearance of license or upfront payments would reflect partnership economics, while continued absence of revenue would remain consistent with the present clinical-stage model. Pipeline disclosures in regulatory filings matter more than small swings around loss estimates because approvals and collaborations are the route from research expense to durable economics.
What the records here don't tell us
- No quarterly income statement is held for PRAX.
Checked against the records this page reads, on the dates shown above.
How does Praxis Precision Medicines compare with its peers?
Short answer
Praxis Precision Medicines's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
The relevant comparison is with clinical-stage central nervous system developers rather than profitable pharmaceutical companies. Praxis combines small molecules that modulate distinct neuronal channels and receptors with antisense programs aimed at genetically defined epilepsies, supported by licensing and research alliances.
That breadth spreads scientific effort across different mechanisms, but it does not create diversification comparable with marketed products. Current financial performance is still driven by pipeline spending and episodic collaboration revenue, so comparisons based on sales growth or conventional earnings multiples miss what the business presently produces.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| Praxis Precision Medicines (PRAX) — this page | $310.90 | $8.69B | 60 |
| $37.56 Nov 19, 2026 | $3.69B | 56 5-pillar Nov 18, 2026 | |
| $32.52 Nov 19, 2026 | $6.73B | 25 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $162.00 – $1201.00
- Consensus target
- $656.60
- Median target
- $616.00
- Revenue estimate
- $634,320
- EPS estimate
- $-13.48
Consensus record · Captured .
Measured against a quoted price of $310.90 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 8, 2026
- Transactions
- 34
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 12
- Other transactions
- 22
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 358 Period end Sep 30, 2026
- Previous quarter · holders
- 332 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Janus Henderson Group Ltd. | 3,449,950 |
| Fmr LLC | 2,637,857 |
| Blackrock, INC. | 2,232,814 |
| Perceptive Advisors LLC | 2,024,781 |
| Baker Bros. Advisors LP | 1,753,198 |
Tracked investors
Which of the 16 named investors we follow held PRAX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PRAX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Praxis Precision Medicines (PRAX)?
What Investors Ask About Praxis Precision Medicines (PRAX) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is Praxis trying to change with its GABAA program?
The program uses an extrasynaptic-preferring positive allosteric modulator intended to alter inhibitory neuronal signaling, with development directed toward major depressive disorder and perimenopausal depression.
How does Praxis approach essential tremor?
Praxis is evaluating a selective inhibitor of T-type calcium channels, making control of abnormal neuronal activity the therapeutic mechanism rather than treatment of a commercial product market.
Why can Praxis report no revenue while advancing central nervous system medicines?
Its candidates remain investigational, so development activity appears mainly as research expense. Historical revenue has come from license and upfront payments rather than recurring medicine sales.
What distinguishes Praxis’s antisense epilepsy work?
The portfolio includes antisense development aimed at gain-of-function genetic epilepsies, complemented by research and licensing relationships with Ionis Pharmaceuticals and the Florey Institute. This adds a genetically targeted modality alongside the company’s small-molecule channel and receptor programs.
What is the PRAX stock price today?
The last price recorded for Praxis Precision Medicines, Inc. (PRAX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PRAX price target?
The analyst consensus price target for Praxis Precision Medicines, Inc. (PRAX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 69 figures on this page — 1 from SEC filings and earnings calls, 59 from Financial Modeling Prep (FMP), 6 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold PRAX
Funds in our ETF coverage that list PRAX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.